Research Strategy and Studies

A summary of our 2018-2021 research strategy can be viewed here.

The list below shows current studies in the Academic Directorate of Respiratory Medicine. For further information please contact lisa.watson24@nhs.net

Abbreviations:

CF – Cystic Fibrosis
COPD – Chronic Obstructive Pulmonary Disease
ILD – Interstitial Lung Disease
Inf / Imm - Inflammation & Immunity
PH – Pulmonary Hypertension
MRC - Medical Research Council
NIHR – National Institute for Health Research

For further information please contact lisa.watson24@nhs.net

Theme	Principal Investigator	Title	Funder
Asthma	Sabroe	Screening of target genes for polymorphic variation which may alter treatment response for airway management	Asthma UK
Asthma	Sabroe	Study of mechanisms of action of Omalizumab in severe asthma	Novartis Pharmaceuticals UK Ltd
Asthma	Sabroe	An observational study of the use of lung MRI imaging for patient benefit	MRC
Asthma	Sabroe	Co-morbidity and refractory asthma - data from a UK registry	BTS Asthma Registry
CF	Edenborough	Cystic Fibrosis Registry	Cystic Fibrosis Trust
CF	Wildman	ACtiF - Adherence to treatment in adults with Cystic Fibrosis 2.1C	NIHR Programme Grants
CF	Wildman	CF Health Hub Data Observatory	NHS England
CF	Wildman	Hyperpolarised gas MRI and multiple breath inert gas washout to improve management and understanding of cystic fibrosis lung disease.	NIHR
CF	Wildman	A pilot study to investigate the role of self-monitoring symptoms using daily diaries, to increase adherence to nebuliser treatments in adults with Cystic Fibrosis	Sheffield Hallam University
COPD	Lawson	Lung magnetic resonance Imaging with FluorocarbonTracer gases	Medical Research Council
COPD	Lawson	A Phase IIb, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of COPD	GlaxoSmithKline
ILD	Bianchi	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the addition of Co-trimoxazole (EME-TIPAC)	NIHR Efficacy and Mechanism Evaluation Programme
ILD	Bianchi	Investigation into prognostic indicators of Idiopathic Pulmonary Fibrosis using structural-functional pulmonary MRI assessment	NIHR
ILD	Bianchi	Functional MRI and PETCT in Idiopathic Pulmonary Fibrosis	NIHR
ILD	Bianchi	A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment	Boehringer Ingelheim Ltd
ILD	Bianchi	Development of imaging biomarkers for the detection and monitoring of drug induced interstitial lung disease (TRISTAN)	European Innovative Medicines Initiative
ILD	Bianchi	Multi-center, international, double-blind, two-arm, randomized, placebo-controlled phase II trial of pirfenidone in patients with unclassifiable progressive fibrosing ILD	Hoffman-La Roche
ILD	Renshaw	Identification of disease susceptibility genes and autoantibodies associated with the development and clinical characteristics of interstitial lung disease (ILD) in patients with and without proven connective tissue diseases (CTDs).	University of Liverpool
Inf/Imm	Sabroe	The control of innate immunity, host pathogen interactions, and leukocyte function in healthy volunteers	Medical Research Council
Mesothelioma	Lewis	Randomised controlled trial to compare the diagnostic yield of Positron Emission Tomography Computed Tomography TARGETed pleural biopsy versus CT guided pleural biopsy in suspected pleural malignancy	North Bristol NHS Trust
PH	Armstrong	Evaluation of patient experiences of Inhaled Iloprost using the Breelib nebulizer	Pulmonary Hypertension Association
PH	Charalampopoulos	SERENADE: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease	Actelion Pharmaceuticals
PH	Condliffe	Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) merit	Actelion Pharmaceuticals
PH	Condliffe	A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without endothelin receptor antagonist (ERA), but not at treatment goal (REPLACE)	Bayer Plc
PH	Kiely	Assessing the Spectrum of Pulmonary Hypertension In a Referral Centre (ASPIRE)	STH NHS FT
PH	Kiely	Freedom 304: TDE-PH-304: “An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension	United Therapeutics Corporation
PH	Kiely	Pilot study: Use of Functional MRI to understand the pathophysiology of abnormalities of gas exchange in patients with idiopathic pulmonary fibrosis and systemic sclerosis	UoS Department
PH	Kiely	Sheffield Pulmonary Hypertension Biobank	British Heart Foundation
PH	Kiely	National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension	BHF/MRC
PH	Kiely	Isolation and characterisation of blood-derived progenitor cells in patients with cardiovascular disease and TGF-beta superfamily related diseases	MRC
PH	Kiely	A prospective, multicenter, single-arm, open-label, Phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic resonance imaging - REPAIR	Actelion Pharmaceuticals
PH	Kiely	Investigation into predictors of diagnosis in PAH patients	IQVIA / GSK
PH	Kiely	A multi-center, double-blind, placebo-controlled, Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient’s self-reported symptoms and their impacts (TRACE trial)	Actelion Pharmaceuticals
PH	Rothman	Clinical evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) system for pulmonary artery denervation in patients with pulmonary hypertension. (TROPHY)	Sonivie
PH	Swift	Reproducibility of Magnetic resonance imaging cardiopulmonary metrics in healthy volunteers and patients with pulmonary arterial hypertension – Implications for trial design	GSK